Back
NovoCure Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
29
NVCR
NovoCure
Last Price:
17.15
Seasonality Move:
10.33%
Buy
51
ALNY
Alnylam Pharmaceuticals
Last Price:
242.97
Seasonality Move:
20.36%
Sell
29
NovoCure (NVCR)
is a Sell
Is NovoCure a Buy, Sell or Hold?
- The current NovoCure [NVCR] share price is $17.11. The Score for NVCR is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.
- NVCR is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Buy
51
Alnylam Pharmaceuticals (ALNY)
is a Buy
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $243.08. The Score for ALNY is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
- ALNY is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
NVCR Stock Price Chart
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $243.08
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
NVCR Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.59 | Sell |
| Relative Strength Index (14 RSI): | 32.44 | Sell |
| Chaikin Money Flow: | -2048068 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (18.95 - 22.75) | Sell |
| Bollinger Bands (100): | (13.24 - 20.16) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 22.91 | Buy |
| Relative Strength Index (14 RSI): | 86.77 | Buy |
| Chaikin Money Flow: | -1210062 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (135.8 - 205.74) | Buy |
| Bollinger Bands (100): | (136.44 - 176.64) | Buy |
NVCR Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 18.42 | Sell |
| 20-day SMA: | 20.46 | Sell |
| 50-day SMA: | 18.54 | Sell |
| 200-day SMA: | 15.41 | Buy |
| 8-day EMA: | 18.43 | Sell |
| 20-day EMA: | 19.52 | Sell |
| 50-day EMA: | 18.85 | Sell |
| 200-day EMA: | 21.61 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 209.44 | Buy |
| 20-day SMA: | 176.25 | Buy |
| 50-day SMA: | 159.62 | Buy |
| 200-day SMA: | 165.96 | Buy |
| 8-day EMA: | 218.01 | Buy |
| 20-day EMA: | 188.75 | Buy |
| 50-day EMA: | 168.9 | Buy |
| 200-day EMA: | 168.09 | Buy |
NovoCure Earnings Growth & NVCR Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.11 per share, an increase next quarter of $0.00 per share, an increase this year of $0.42 per share, and a decrease next year of $0.11 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.12 per share, a decrease this year of $0.46 per share, and an increase next year of $1.83 per share.
NovoCure Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||